Literature DB >> 8914032

Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. The Collaborative Study Group.

J A Breyer1, R P Bain, J K Evans, N S Nahman, E J Lewis, M Cooper, J McGill, T Berl.   

Abstract

We designed a prospective, double-blind controlled trial to determine predictors of loss of renal function in patients with insulin dependent diabetes and established nephropathy. A total of 409 insulin-dependent diabetic patients with established nephropathy enrolled in a trial on the effect of Captopril on the rate of progression of renal disease. Baseline demographic, clinical (history and physical) and laboratory parameters were analyzed as risk factors for time to progression. Dichotomous characteristics were compared by Fisher's exact test and continuous characteristics with the Wilcoxon rank-sum test. Univariate proportional hazards regression analysis was used to estimate relative risk of nephropathy progression, and bivariate proportional hazard regression to identify interactions with the treatment group assignment. Multivariate proportional hazard regression was employed to determine which characteristics were independent risk factors. We found that a number of demographic and clinical characteristics were significantly associated with nephropathy progression even after adjustment for treatment group. However, after multivariate analysis, the risk factors that independently predicted progression were onset of IDDM later in life, parental diagnosis of IDDM, the presence of edema, increased mean arterial pressure, and an abnormal electrocardiogram. Likewise, a number of laboratory characteristics were also predictive of nephropathy progression. A low hematocrit, high blood sugar, and higher protein excretion predicted nephropathy progression as did a higher serum creatinine, particularly in the face of a normal serum albumin. In conclusion, this study identifies a number of clinical and laboratory risk factors that can predict which patients with insulin-dependent diabetes with established nephropathy are more likely to sustain a clinically important decrease in renal function over a median follow-up of three years.

Entities:  

Mesh:

Year:  1996        PMID: 8914032     DOI: 10.1038/ki.1996.481

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  41 in total

Review 1.  The impact of evidence-based medicine on diabetes therapy.

Authors:  Phillip Gorden; Carla Musso
Journal:  Curr Diab Rep       Date:  2005-06       Impact factor: 4.810

2.  Midkine, a heparin-binding protein, is increased in the diabetic mouse kidney postmenopause.

Authors:  Maggie K Diamond-Stanic; Melissa J Romero-Aleshire; Patricia B Hoyer; Kevin Greer; James B Hoying; Heddwen L Brooks
Journal:  Am J Physiol Renal Physiol       Date:  2010-11-03

3.  Evidence-based practice guideline for the treatment of CKD.

Authors: 
Journal:  Clin Exp Nephrol       Date:  2009-12       Impact factor: 2.801

4.  Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005.

Authors:  P Rossing
Journal:  Diabetologia       Date:  2005-12-09       Impact factor: 10.122

5.  Differential regulation of circulating and renal ACE2 and ACE in hypertensive mRen2.Lewis rats with early-onset diabetes.

Authors:  Liliya M Yamaleyeva; Shea Gilliam-Davis; Igor Almeida; K Bridget Brosnihan; Sarah H Lindsey; Mark C Chappell
Journal:  Am J Physiol Renal Physiol       Date:  2012-02-29

Review 6.  The relationship between glucose control and the development and progression of diabetic nephropathy.

Authors:  Carrie A Phillips; Mark E Molitch
Journal:  Curr Diab Rep       Date:  2002-12       Impact factor: 4.810

Review 7.  Angiotensin II and the glomerulus: focus on diabetic kidney disease.

Authors:  James W Scholey
Journal:  Curr Hypertens Rep       Date:  2003-04       Impact factor: 5.369

Review 8.  Sex, diabetes and the kidney.

Authors:  Christine Maric
Journal:  Am J Physiol Renal Physiol       Date:  2009-01-14

9.  Cost effectiveness of ACE inhibitor treatment for patients with type 1 diabetes mellitus.

Authors:  Frederick B Dong; Stephen W Sorensen; Diane L Manninen; Theodore J Thompson; Venkat Narayan; Carlyn E Orians; Edward W Gregg; Richard C Eastman; Erik J Dasbach; William H Herman; Jeffrey M Newman; Andrew S Narva; David J Ballard; Michael M Engelgau
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

10.  Higher levels of urinary albumin excretion within the normal range predict faster decline in glomerular filtration rate in diabetic patients.

Authors:  Tetsuya Babazono; Izumi Nyumura; Kiwako Toya; Toshihide Hayashi; Mari Ohta; Kumi Suzuki; Yuka Kiuchi; Yasuhiko Iwamoto
Journal:  Diabetes Care       Date:  2009-05-12       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.